Can we finally get ahead of drug shortages?

In this episode of Denatured, Christina Smolke, co-founder & CEO at Antheia and Kyle Pudenz, SVP and head of data & AI product at Cencora explore why drug shortages are getting worse, and how combining predictive supply-chain analytics with agile, distributed manufacturing could finally make essential medicines more resilient and accessible.
Brewing the Future of Medicine

From their early days working together at Caltech to building a company that is bringing groundbreaking science into commercial reality, Christina Smolke, Co-Founder & CEO and Kristy Hawkins, Co-Founder & Chief Scientific Officer of Antheia share the remarkable journey behind Antheia.
How to tell if your scientific breakthrough can be a viable business

Scientific research and starting a company require very different skills, but they have at least one thing in common: They both require years of hard work with no guarantee it’ll pay off.
Antheia lands $80M conditional loan from Trump administration to onshore drug manufacturing

Next-gen manufacturer Antheia is teaming up with the U.S. Department of War to build out its infrastructure and onshore the U.S. drug supply chain.
Antheia gets $80M conditional DOD loan to onshore to the US

Biosynthesis manufacturer Antheia has won a conditional loan of $80 million from the US Department of Defense to help boost the domestic production of generic drugs.
Antheia Secures $80 Million Conditional Funding Commitment from Department of War’s Office of Strategic Capital
Financing supports Antheia’s domestic manufacturing strategy to onshore critical medicine supply chains MENLO PARK, CA – October 18, 2026 – Antheia, the advanced biosynthesis company delivering 21st-century pharmaceutical manufacturing and innovation, today announced it has received a conditional commitment from the U.S. Department of War’s Office of Strategic Capital (OSC) for a direct, long-term loan […]
Antheia Secures Additional $9 Million in Expanded BioMaP-Consortium Project Agreement to Onshore Pharmaceutical Supply Chains
U.S. government fortifies commitment to advanced manufacturing technology for the domestic production of essential medicines MENLO PARK, Calif., March 4, 2026 – Antheia, the advanced biosynthesis company delivering 21st-century pharmaceutical manufacturing and innovation, today announced it has expanded the scope of its second project agreement with the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), securing an additional $9 million. The additional funds bring the total project investment to $21 […]
Antheia’s 2025 in Review: A Year Of Momentum

As 2025 draws to a close, we’re reflecting on a year defined by momentum. With commercial products to market and a growing ecosystem of partners, we are continuing to realize our vision for a new era of pharmaceutical manufacturing and innovation. Through advanced biosynthesis, we’re transforming how the pharmaceutical industry develops and manufactures the medicines the world needs. […]
Antheia Appoints Eric d’Esparbes as Chief Financial Officer
d’Esparbes to lead Antheia’s financial strategy as the company continues its global expansion and commercialization MENLO PARK, Calif., October 21, 2025 — Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced the appointment of Eric d’Esparbes as Chief Financial Officer. d’Esparbes will oversee Antheia’s financial strategy and operations as the company advances […]
Antheia’s 2024 in Review: A Year Of Collaboration

As we reflect on 2024, it’s been a significant year of collaboration, with every Antheia employee and partner helping us move closer toward our mission of transforming pharmaceutical supply chains and ending essential medicine shortages. No one person, company, or organization can solve a daunting global problem like drug shortages alone, but we have made […]